7-29884000-C-T
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_001080529.3(WIPF3):c.506C>T(p.Pro169Leu) variant causes a missense change. The variant allele was found at a frequency of 0.000243 in 1,527,954 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.000073 ( 0 hom., cov: 30)
Exomes 𝑓: 0.00026 ( 0 hom. )
Consequence
WIPF3
NM_001080529.3 missense
NM_001080529.3 missense
Scores
1
9
9
Clinical Significance
Conservation
PhyloP100: 4.31
Genes affected
WIPF3 (HGNC:22004): (WAS/WASL interacting protein family member 3) Predicted to enable SH3 domain binding activity and actin binding activity. Predicted to be involved in actin filament-based movement. Predicted to be located in cytosol. Predicted to be active in actin filament. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.218247).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
WIPF3 | NM_001080529.3 | c.506C>T | p.Pro169Leu | missense_variant | 5/9 | ENST00000242140.10 | NP_001073998.2 | |
WIPF3 | NM_001391973.1 | c.506C>T | p.Pro169Leu | missense_variant | 5/8 | NP_001378902.1 | ||
WIPF3 | XM_017012522.2 | c.473C>T | p.Pro158Leu | missense_variant | 4/8 | XP_016868011.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
WIPF3 | ENST00000242140.10 | c.506C>T | p.Pro169Leu | missense_variant | 5/9 | 5 | NM_001080529.3 | ENSP00000242140.6 | ||
WIPF3 | ENST00000409123.5 | c.506C>T | p.Pro169Leu | missense_variant | 5/8 | 5 | ENSP00000386790.1 |
Frequencies
GnomAD3 genomes AF: 0.0000730 AC: 11AN: 150750Hom.: 0 Cov.: 30
GnomAD3 genomes
AF:
AC:
11
AN:
150750
Hom.:
Cov.:
30
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000909 AC: 12AN: 131960Hom.: 0 AF XY: 0.000126 AC XY: 9AN XY: 71250
GnomAD3 exomes
AF:
AC:
12
AN:
131960
Hom.:
AF XY:
AC XY:
9
AN XY:
71250
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000261 AC: 360AN: 1377204Hom.: 0 Cov.: 34 AF XY: 0.000263 AC XY: 178AN XY: 677376
GnomAD4 exome
AF:
AC:
360
AN:
1377204
Hom.:
Cov.:
34
AF XY:
AC XY:
178
AN XY:
677376
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000730 AC: 11AN: 150750Hom.: 0 Cov.: 30 AF XY: 0.0000136 AC XY: 1AN XY: 73522
GnomAD4 genome
AF:
AC:
11
AN:
150750
Hom.:
Cov.:
30
AF XY:
AC XY:
1
AN XY:
73522
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
ExAC
AF:
AC:
4
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 31, 2024 | The c.506C>T (p.P169L) alteration is located in exon 5 (coding exon 4) of the WIPF3 gene. This alteration results from a C to T substitution at nucleotide position 506, causing the proline (P) at amino acid position 169 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Uncertain
.;D;D
Eigen
Uncertain
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
T;T;.
M_CAP
Uncertain
D
MetaRNN
Benign
T;T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
.;M;M
PrimateAI
Pathogenic
D
PROVEAN
Uncertain
D;D;D
REVEL
Benign
Sift
Uncertain
D;D;D
Sift4G
Uncertain
D;D;D
Polyphen
1.0
.;D;D
Vest4
MutPred
Loss of relative solvent accessibility (P = 0.008);Loss of relative solvent accessibility (P = 0.008);Loss of relative solvent accessibility (P = 0.008);
MVP
MPC
0.41
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at